Please assess the completion status of the following clinical trial:

Trial Title: On-X Heart Valve - 17mm Aortic and 23mm Mitral

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of any age; unless waived by local IRB assent of the patient and in all cases consent of parent or legally authorized representative is required if a patient is under the age of majority and not legally emancipated.~2. Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups.~3. Patients who are in sufficient satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively).~4. Patients who require an isolated aortic valve replacement size 17 mm or isolated mitral valve replacement size 23mm.~5. Patients who are geographically stable and willing to return to the implanting center for follow-up visits.~6. Patients or legally authorized representatives who are adequately informed of their participation in the clinical study and what will be required of them in order to comply with the protocol.~7. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be included in the study.~Exclusion Criteria:~1. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient.~3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison inmates.~4. Patients with a previous prosthetic valve, where it is not being replaced by a study valve, or patients requiring multiple valve replacement.~5. Patients with active endocarditis or active myocarditis. 6 Patients who require tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the required number of follow-up visits or who are geographically unavailable for follow-up.~8. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with non-cardiac illness resulting in a life expectancy of less than 1-year.~10. Patients previously enrolled and implanted in this trial may not re-enter after withdrawal.~11. Patients already enrolled in another investigational device or drug study (nor can enrolled patients be enrolled in other studies).~12. Patients with acute preoperative neurological deficit, myocardial infarction, or cardiac event who have not returned to baseline for at least 30-days prior to enrollment.~13. Patients with aortic aneurysm or other medical condition that creates a higher than usual risk of surgical complication.~14. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of understanding their assent as judged by the principal investigator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 17mm On-X Aortic Heart Valve (Type: EXPERIMENTAL): Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
- 23mm On-X Mitral Heart Valve (Type: EXPERIMENTAL): Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.~Enrollment into the 23mm On-X mitral arm has been terminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues